The SLC17A6 gene gives nerve cells instructions to package glutamate, a key brain signaling chemical, so messages can pass between cells. If this gene does not work properly, brain signaling can be disrupted, which can lead to seizures, developmental delay, and problems with movement or muscle tone. The protein made by this gene helps your cells send activating signals at the right time. Certain variants in the SLC17A6 gene are linked to rare neurodevelopmental conditions, including developmental and epileptic encephalopathy.
What is a gene?
A gene is a stretch of DNA that gives your cells instructions they can use to make molecules or regulate activities in the body. Some genes carry the code for proteins, which do much of the cell’s work. Other genes mainly direct when certain processes happen, where they take place, and how active they are. Taken together, genes affect how the body develops and functions, and they can influence how you respond to food, stress, or medications. For a more detailed look at this topic, you can find more in the LearnHub.
Overview
SLC17A6Gene function
What if the gene works
The SLC17A6 gene helps nerve cells package glutamate, a key brain messenger, into tiny sacs for release. This supports normal communication in parts of the brain and nervous system.
Risk
What if the gene does not work
Variants in the SLC17A6 gene can disrupt glutamate signaling in the brain, leading to developmental delay, low muscle tone, movement differences, and sometimes epilepsy. Milder and more severe variants may shape when symptoms begin and how marked they are.
Treatment
What does that mean for your treatment
No treatment or management approach specific to the SLC17A6 gene is currently established. The SLC17A6 gene is being studied as a possible drug target because it affects glutamate, a key brain signaling chemical, but this work remains early and does not guide routine treatment.
Gene function
What if the gene works
Many of your brain's quick messages depend on glutamate, a major activating chemical signal. The SLC17A6 gene provides instructions for a transporter that packs glutamate into tiny storage sacs inside nerve cells. This allows signals to pass efficiently from one nerve cell to the next. It supports everyday functions such as movement, breathing, sensation, and alertness.
The SLC17A6 gene makes a transporter that moves glutamate into tiny storage sacs inside nerve cells. This step prepares glutamate, one of the brain's main activating messengers, for release.
When a nerve cell fires, those filled sacs can merge with the cell surface and release glutamate to the next cell. This is how the SLC17A6 gene helps nerve cells release glutamate for fast communication.
By stocking these sacs efficiently, this gene supports steady signaling across brain and spinal cord circuits. These everyday messages help coordinate movement, breathing, sensation, and alertness.
What is a variant?
A genetic variant is a slight change in a gene’s DNA sequence. These changes are common and are one reason people naturally differ from one another, including in appearance, metabolism, and how the body responds to environmental influences. Many variants do not have any obvious effect and simply reflect normal genetic variation. At times, however, a variant can more noticeably change how a gene functions and may contribute to or cause a genetic condition.
Genetic variants
What if the gene does not work
Variants in the SLC17A6 gene can alter the transporter protein’s shape, stability, or delivery to the right part of the nerve cell, which may reduce how much of the chemical messenger glutamate gets packed into release vesicles (tiny storage sacs). In practical terms, this is how SLC17A6 gene variants affect protein function at the cell level. Milder variants may leave some transport activity, while more disruptive variants can sharply reduce or nearly abolish it.
How variants are linked to conditions
Pathogenic variants in the SLC17A6 gene can cause a rare neurodevelopmental condition often described as developmental and epileptic encephalopathy. Published reports link variants in the SLC17A6 gene to conditions marked by developmental delay, seizures, speech differences, and sometimes movement problems, although the pattern and severity can vary from person to person.
A variant is not necessarily a diagnosis
Genetic variants are common across the general population and are a normal feature of human biology. Most do not directly affect health and simply reflect natural variation among people. In many genes, having a variant associated with a condition suggests a possible link rather than a certain diagnosis, particularly when several genes and environmental influences play a role. In other situations, a single well-characterized variant in one specific gene is enough to confirm a diagnosis.
Are there things that can increase or change my risk?
There is not yet broadly confirmed evidence on specific factors that increase or reduce health risk related to the SLC17A6 gene. For many living with a disease-causing change in SLC17A6, the gene change itself is the main driver, while symptoms can still vary from one person to another.
Inheritance of SLC17A6 variants
Understanding SLC17A6 gene inheritance helps explain why this condition often appears in just one person in a family. Disease causing variants in the SLC17A6 gene are inherited in an autosomal dominant pattern, so a parent carrying the variant can pass it to each child with a 50% chance. Some people have a new, de novo variant in the SLC17A6 gene, which means it was not inherited from either parent. In those cases, the chance for future children usually depends on whether a parent also carries the variant.
What does my SLC17A6 result mean for my family?
There is not yet a broadly confirmed inheritance pattern tied to a specific condition for SLC17A6 in the way there is for some better-known genes. If you have a specific SLC17A6 result and questions about what it could mean for your family, a doctor or genetic counselor can help explain whether relatives might also want to review their own results or family history.
Genetic information
Genetic testing
How you find out about variants
To find out whether you carry a variant in the SLC17A6 gene, clinicians use genetic testing for SLC17A6 variants on a blood or saliva sample. A lab reads your DNA sequence and checks for changes, then reports whether it found a variant linked to disease, a harmless variant, or one whose meaning is still unclear.
When should I consider getting a genetic test?
Testing for the SLC17A6 gene may be considered when a child has unexplained developmental delay, learning problems, movement symptoms, or seizures, especially if other causes have not been found. It can also be relevant when a similar pattern appears in close family members.
A genetic result is only one part of your health story
A genetic result can give useful insight, but how much it explains depends on the condition and the type of variant involved. Lifestyle, environment, age, and medical history also shape how the body works over time. For some conditions, especially those influenced by many genes, genetic information offers context rather than certainty and is best viewed with other parts of care. In other situations, a genetic result may give a clear answer. In areas like medication response, genetic results can help make sense of individual experiences.
Pharmacogenetics
How variants shape your response to medicine
Genetic variation can affect how people respond to medicines. One person may break down a drug more slowly or more quickly than another, which can change how strongly it works or how likely side effects are. These differences are common and can influence both benefit and sensitivity, even when two people take the same treatment.
What is Pharmacogenetics?
Pharmacogenetics examines how differences in a person’s genes can shape their response to medicines. By studying relationships between genes and medications, it helps explain why the same treatment may not work the same way for everyone. For many drugs, genes can influence how the body handles a medicine or how much effect it has. This information can support treatment choices that are more informed and tailored to the individual. More detailed information on this topic is available in the LearnHub.
Drugs influenced by the SLC17A6 gene
When should I seek medical advice?
There is not yet a broadly confirmed role for this gene in guiding medication choice or dose. Questions about side effects, trouble tolerating a medicine, or concerns about how treatment may affect you are best discussed with your doctor.
History
For many years, scientists knew glutamate was a major brain signaling chemical, but they needed tools to identify the nerve cells that package and release it. In the early 2000s, researchers identified the SLC17A6 gene as the gene for vesicular glutamate transporter 2, often called VGLUT2. Building on this early work, scientists used SLC17A6 to map glutamate using nerve pathways across the brain and spinal cord. That helped settle long standing questions about which groups of nerve cells use glutamate as their main messenger. The gene became especially important in neuroscience research because it gave researchers a reliable marker for studying brain circuits in animals and human tissue. Over time, descriptions became more precise as related glutamate transporter genes were also identified.